Arrigoni E, Benzi G, Dagani F, Falconi G, Mandelli V, Moretti A, Scelsi R, Villa R F
Arzneimittelforschung. 1979;29(8a):1231-8.
A test model of studying the effects of chronic pharmacological treatment on cerebral metabolism related to energy transduction was developed. The most useful biochemical parameters were the cerebral enzymatic activities related to the glycolytic pathway (lactate dehydrogenase), the Krebs' cycle (citrate synthetase and malate dehydrogenase) and the electron transfer chain (total NADH-cytochrome c reductase and cytochrome oxidase). The model is based on the natural growth-dependent changes occurring in the rat during aging (from 10 to 60 weeks of life). As test drug, 10-methoxy-1,6-dimethyl-ergoline-8 beta-methanol-(5-bromonicotinate) (nicergoline, Sermion) was administered daily for three periods of 16 weeks each (10-26, or 28-44, or 44-60 weeks of life) by two different administration routes (oral and i.p.), and at two different dose levels: oral 1 or 4, i.p. 0.25 or 1 mg/kg. Biochemical data were obtained blindly after 4, 8, 12 and 16 weeks of treatment. The drug tested exerted different effects which were dependent on the various administration periods and the administration routes. No dose-effect relationship was established.
建立了一个研究长期药物治疗对与能量转导相关的脑代谢影响的测试模型。最有用的生化参数是与糖酵解途径(乳酸脱氢酶)、三羧酸循环(柠檬酸合酶和苹果酸脱氢酶)以及电子传递链(总NADH-细胞色素c还原酶和细胞色素氧化酶)相关的脑酶活性。该模型基于大鼠衰老过程中(10至60周龄)自然发生的与生长相关的变化。作为测试药物,10-甲氧基-1,6-二甲基-麦角灵-8β-甲醇-(5-溴烟酸酯)(尼麦角林,喜得镇)通过两种不同给药途径(口服和腹腔注射),在两个不同剂量水平:口服1或4mg/kg、腹腔注射0.25或1mg/kg,在三个16周的时间段(分别为10 - 26周、28 - 44周或44 - 60周龄)内每日给药。在治疗4、8、12和16周后盲目获取生化数据。所测试的药物产生了不同的效果,这些效果取决于不同的给药时间段和给药途径。未建立剂量-效应关系。